

FORWARD-LOOKING STATEMENTS

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This presentation contains forward-looking statements regarding future events and the future results of Pasithea Therapeutics Corp. ("Pasithea" or the "Company") that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. Words such as "address," "anticipate," "believe," "consider," "continue," "develop," "estimate," "avpect," "further," "goal, "intend," "may," "plan," "potential," "project," "seek," "should," "target," "will," variations of such words, and similar expressions are intended to identify such forward-looking statements. Such statements reflect the current views of the Company and its management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance, or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. This presentation has been prepared by the Company based on information it has obtained from sources it believes to be reliable. Summaries of documents contained in this presentation may not be complete. This presentation contains industry, market and competitive position data from our own internal estimates and research as well as industry and general publications and research surveys and studies conducted by third parties. Industry conditions. While we believe to be reliable, although they do not guarantee the accuracy or completeness of such information. Our internal estimates are based upon information obtained from trade and business organizations and other contacts in which we operate and our management's understanding of industry conditions. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. While

This presentation contains projected financial information with respect to the Company. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainities that could cause actual results to differ materially from those contained in the prospective financial information. Actual results may differ materially from the results contemplated by the projected financial information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such projected.

This presentation may not be copied or reproduced in whole or in part. By accepting delivery of this presentation, you agree to these restrictions.

We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this communication relates. The registration statement has not yet become effective. Before you invest, you should read the preliminary prospectus in that registration statement (including the risk factors described therein) and other documents that we have filed with the SEC for more complete information about us and the offering. We encourage you to read the registration statement and the prospectus in full for more detailed information on the statistics, reports, studies, and clinical trials references in this presentation.

You may access these documents for free by visiting EDGAR on the SEC Website at http://www.sec.gov. Alternatively, we or any underwriter participating in this offering will arrange to send you the prospectus if you contact Dr. Tiago Reis Marques, Chief Executive Officer, at (702) 514-4174, or EF Hutton, division of Benchmark Investments, LLC, 590 Madison Ave., 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicategroup@efhuttongroup.com or telephone at (212) 404-7002.



OFFERING SUMMARY

Issuer:	Pasithea Therapeutics Corp.		
Proposed Exchange / Tickers:	Nasdaq Capital Market / KTTA, KTTAW		
Offering Type:	Underwritten Initial Public Offering		
Securities Issued:	Units, consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock		
Gross Offering Proceeds (including Over- Allotment):	Up to \$23.3 Million		
Over-Allotment:	15%		
Estimated Offering Price Range:	\$5.00 - \$7.00 per Unit		
Pre-Money FD Shares Outstanding:	8,258,371 shares*		
Anticipated Use of Proceeds:	Fund pre-clinical research and development work for future product candidates, development of U.S. and U.K. clinical businesses, IP, business costs, working capital, and selling, general and administrative purposes		
Sole Book-Running Manager:	EF Hutton, division of Benchmark Investments, LLC		
Expected Close:	Q3 2021		
COPYRIGHT © 2021 PASITHEA			

INTRODUCTION TO PASITHEA THERAPEUTICS

Pasithea Therapeutics is

a biotech company at the forefront of neuroscience research



Complementary Two-Pronged Business Model

Improving treatment options for those affected by mental illness

1. PRIMARY FOCUS:



Drug development: Focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders

2. SECONDARY FOCUS:



Clinic partnerships: Focused on providing business support services to anti-depression clinics in the UK and in the US¹

Become a market leader in designing and delivering safe and effective treatments to patients in need

¹ Operations have yet to commence (please see Slides 10-13 for further detail on status).



INVESTMENT HIGHLIGHTS



Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology



Dr. Lawrence Steinman. Executive Chairman & Co-Founder

- · Endowed Chair in the Neurology Dept. at Stanford University
- Founded several successful biotech companies Drug development pioneer



Dr. Tiago Reis Marques, CEO & Director

 Fellow at Imperial College and lecturer at King's College London Renowned psychiatric researcher and lecturer with decades of experience in the biological mechanisms of mental health and brain disorders

Dr. Yassine Bendiabdallah, COO, Head of UK Clinics & Director

- · PhD in Medicinal Chemistry from University College London
- Extensive experience in the design and synthesis of novel drug candidates



Large Addressable Market With Few **Options for Adequate Help Today**



Capital-Light Infrastructure



Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential



COPYRIGHT © 2021 PASITHEA

LARGE AND GROWING ADDRESSABLE MARKET



Estimated number of adults suffering from some type of mental health issue in the U.S.1



US\$19.2 Billion

Estimated size of anxiety and depression market by 20273




Trillion

Lost between 2010 and 2030 due to mental health conditions²



Up 33%

Depression diagnoses in the US have increased 33% between 2013 and 20164



- · Mental health problems skyrocketed globally in 2020.
- Reduced social contact exacerbated feelings of isolation for many people.
- Reported thoughts of suicide are higher than ever before.

Effective treatments for mental health are more needed today than ever before.

¹National Institute of Mental Health

National Institute of Mental Health Hanavid School of Public Health in 2011: The Global Economic Burden of Non-communicable Disease Reports and Data: Anxiety Disorder and Depression Treatment Market by Therapies Halue Cross Blue Shield: Major Depression: The Impact on Overall Health Cisclester ME, Lane RJ, Petrosky E, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1049– 477. 1057



THE STARK REALITY OF THE GLOBAL TREATMENT GAP



TREATMENT GAP

> Estimates of the percentage of people with untreated MDD vary widely, ranging from 16% to 84% (median, 56%)¹

> The treatment gap is high even in largely developed regions such as Europe (45%) and the Americas (57%)²

COUNTRIES

TREATMENT

RECEIVED

31.7%4

HIGH-INCOME

1 in 5 people³

I OW-INCOME

1 in 27 people³

Only a minority of participants with Major **Depressive Disorder (MDD) received** minimally adequate treatment




¹Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-866.
²World Health Organization: The treatment gap in mental healthcare
³Thomicroft G, Chatterij S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017;210(2):119-124.
⁴Wells JE, Browne MO, Aguilar-Gaxiola S, et al. Drop out from out-patient mental healthcare in the World Health Organization's World Mental Health Survey initiative. Br J Psychiatry. 2013;202(1):42-49.



COPYRIGHT © 2021 PASITHEA

EVEN THOSE WHO DO GET TREATMENT FACE CHALLENGES



¹Based on randomized double-blind, placebo-controlled clinical trials (RCT) of anti-depressants; Source: PLOS One: A systematic review of comparative efficacy of treatments and controls for depression



PRIMARY FOCUS: DEVELOPING NEW MOLECULAR ENTITIES AND/OR NOVEL BIOLOGIC DRUGS

Drugs targeting novel mechanism of action

	Next 24 MONTHS		
SELECTION OF CANDIDATES	HIT-TO-LEAD STAGE	DISEASE MODELS	CLINICAL TRIALS
Develop 3 lead compounds focused on psychiatric and neurological disorders	Candidate compounds will undergo: • Chemistry characterization • Compound metabolism • Pharmacokinetics • In vitro pharmacology • In vivo pharmacology • Safety assays	Preclinical models of mental illness will be used as the lead compounds are cleared	Phase 1
 Focuses on: Targets that can be developed into a drug Commercial potential of drug 		Research will combine: A conservative approach Lead compounds will be sought on a well- defined target A moonshot approach Completely novel mechanisms of action will be researched	Phase 2
			Phase 3

SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS

COPYRIGHT © 2021 PASITHEA

Will provide intravenous infusions of

ketamine to treat mental health disorders, such as Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD)

Will give immediate access to patients in the UK and US

Capital-light business with a **significant client base**

Diversified revenue stream will help **support R&D efforts** <u>Anticipated Operating Process</u>: Pasithea will seek to repurpose one of the most commonly used medical drugs to bring faster relief to many of those suffering from TRD and PTSD

The Process of Ketamine Infusion Treatment

Infusion

Treatment



Psychiatric Assessment



Psychiatric Follow-up

42-51% Efficacy

of normal anti-depressants – a huge opportunity to improve¹

76% of Patients

Responded to ketamine treatment in treating TRD in one trial²

¹Reports and Data; Harris Bricken; informedhealth.org ²Dwver IB Landeros-Weisenberger A. Johnson IA et al. Efficaci

²Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Am J Psychiatry. 2021;178(4):352-362



asithea

SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS – **UNITED KINGDOM**

Operations in the UK will involve providing business support services to registered healthcare providers who will assess patients and administer IV infusion of ketamine, if appropriate. Operations in the UK will take placement through partnerships with **Zen Healthcare**.

Collaboration Agreements with Purecare Limited and Portman Health Ltd

Pasithea obligations

- Market treatments to extent permitted by law
- Arrange and pay for fit-out of consulting room
- Provide equipment
- Employ/engage customer services advisors to liaise with clinical staff and pay certain staff costs
- Operate and maintain booking website for treatments and take bookings and payment

• Purecare Limited and Portman Health Ltd obligations

- Apply for and maintain CQC registrations
- Provide consulting and treatment rooms and maintain equipment
- Provide pharmaceuticals and equipment for assessing patients and providing treatments
- Employ/engage licensed and qualified staff
- Assess patients and administer treatment, if appropriate

Currently, Pasithea Therapeutics Limited (UK) currently has one employee and will operate under Zen Healthcare's regulatory approvals.



COPYRIGHT © 2021 PASITHEA

UK CLINIC PARTNERSHIP


Highlights:

- · Capital-light partnership with Zen Healthcare
- Zen Healthcare has two locations in London: Knightsbridge and Baker Street
- Provides immediate exposure in the UK
- Existing management structure and qualified GPs, pharmacists, therapists and psychotherapists



Deal Terms:

· Agreement with Zen Healthcare for existing clinics





SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS – **UNITED STATES**

Operations in the US will involve providing business support services to registered healthcare providers who will assess patients and administer IV infusion of ketamine, if appropriate.

Pasithea intends to enter into **Business Support Services Agreements** with professional companies, Nadelson Medical PLLC and Nadelson Medical of CA, P.C.

•Nadelson Medical PLLC is currently being formed

• Pasithea expects to have executed Business Support Services Agreements with both professional companies by September 2021

Pasithea has entered into a Business Support Services Subcontract with The IV Doc.

•The IV Doc will provide certain non-clinical administrative, back office, and other business support services to one or more professional medical practices in New York.

• Pasithea will pay The IV Doc monthly subcontract fees and reimburse The IV Doc for all reasonable expenses.

pasithea

COPYRIGHT © 2021 PASITHEA



Highlights:

- Partnered with The IV Doc, a leading provider of administrative and support services to affiliated clinical practices providing infusions in the US
- Provides rapid exposure & capital-light expansion opportunities in the US
 Potential expansion beyond these cities
- Initial operations in New York
- · Anesthesiologist administers infusion in patients' homes

Deal Terms:

· Plan to market and roll out nationwide





13

PASITHEA'S COMPETITIVE LANDSCAPE IN THE MENTAL HEALTH SECTOR



IMPROVING MENTAL HEALTH TREATMENTS AND DRIVING SHAREHOLDER VALUE



Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology



Large Addressable Market With Few Options for Adequate Help Today



Capital-Light Infrastructure



Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential



Improving treatment options for those affected by mental illness

1. PRIMARY FOCUS:



Drug development: Focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders

2. SECONDARY FOCUS:



Clinic partnerships: Focused on providing business support services to anti-depression clinics in the UK and in the US¹

Become a market leader in designing and delivering safe and effective treatments to patients in need

¹ Operations have yet to commence (please see Slides 10-13 for further detail on status).





www.pasitheaclinics.com

Contact: Ed Tsuker Head of Capital Markets EF Hutton etsuker@efhuttongroup.com

